Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | IDH2 | P48735 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21949867 | 0.92 | PKM (0.49) | HTR2AHTR2CHTR2BPKMRAB9A | |
| SCHEMBL31710999 | 0.89 | HTR2A (0.48) | HTR2AHTR2CHTR2BPKMRAB9A | |
| SCHEMBL983941 | 0.88 | HTR2C (0.51) | HTR2AHTR2CHTR2BPKMBRD4 | |
| SCHEMBL31710828 | 0.85 | PKM (0.49) | HTR2AHTR2CHTR2BPKMRAB9A | |
| SCHEMBL20497372 | 0.83 | PKM (0.50) | HTR2AHTR2CHTR2BPKMRAB9A | |
| SCHEMBL20497371 | 0.83 | PKM (0.50) | HTR2AHTR2CHTR2BPKMRAB9A | |
| SCHEMBL28333031 | 0.82 | HTR2A (0.56) | HTR2AHTR2CHTR2BBRD4RIPK1 | |
| SCHEMBL31710431 | 0.81 | RBP4 (0.50) | PKMRAB9AMAPTKDM4ENPC1 | |
| SCHEMBL1438650 | 0.80 | SCN8A (0.43) | HTR2AHTR2CHTR2BRIPK1IDH2 | |
| SCHEMBL9774749 | 0.80 | ALDH1A1 (0.50) | HTR2AHTR2CHTR2BPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2021-08-05 | — | — | US | disclosed |
| CN-106986872-B | Bromodomain inhibitors | 艾伯维公司 | 2020-04-21 | — | — | CN | disclosed |
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-2797918-B1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2017-11-29 | — | — | EP | disclosed |
| CN-106986872-A | Bromine domain inhibitor | 艾伯维公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-104136435-B | bromodomain inhibitors | 艾伯维公司 | 2017-05-10 | — | — | CN | disclosed |
| US-9376442-B2 | Methylpyrrolopyrimidinecarboxamides | TAKEDA GMBH (DE) | 2016-06-28 | — | — | US | disclosed |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC (US) | 2016-05-26 | — | — | US | disclosed |
| US-9296741-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| WO-2013097601-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| EP-2470536-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2011023693-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-03-03 | — | — | WO | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296566-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HTR2A 2225/4885HTR2C 2369/4885HTR2B 1840/4885 |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | HTR2A 3062/4885HTR2C 1834/4885HTR2B 1921/4885 |
| US-20140162971-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HTR2A 2225/4885HTR2C 2369/4885HTR2B 1840/4885 |
| US-20230158039-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HTR2A 2225/4885HTR2C 2369/4885HTR2B 1840/4885 |
| US-20120142633-A1 | METHYLPYRROLOPYRIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | HTR2A 1891/4885HTR2C 1128/4885HTR2B 1305/4885 |
| US-20160143916-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HTR2A 2225/4885HTR2C 2369/4885HTR2B 1840/4885 |
| US-20210236508-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD1, BRD3 | HTR2A 2225/4885HTR2C 2369/4885HTR2B 1840/4885 |
| US-20120149721-A1 | METHYLPYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE12, PDE4A | HTR2A 2043/4885HTR2C 1115/4885HTR2B 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.